Harmony Biosciences Market Research Report

Company Overview

• Name: Harmony Biosciences

• Mission: Deliver innovative and novel treatments for rare neurological disease communities, guided by core principles of empathy and innovation.

• Founded: 2017

• Founder(s): Information not available

• Key People: Information not available

• Headquarters: Information not available

• Number of Employees: Information not available

• Revenue: Information not available

• Known For: Developing therapeutic innovations especially for sleep/wake disorders, neurobehavioral, and rare epilepsy conditions.

Products

WAKIX® (pitolisant) Tablets

• Description: A registered trademark of Bioprojet Europe, Ltd and approved by the US FDA.

• Key Features:

• Histamine-3 receptor antagonist/inverse agonist.

• Initially developed for treatments of excessive daytime sleepiness and cataplexy in narcolepsy.

• Being evaluated for additional conditions: idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy type 1.

• Two next-generation formulations: Pitolisant GR and Pitolisant HD.

Pitolisant GR

• Feature: Ability to initiate treatment at a therapeutic dose range.

Pitolisant HD

• Feature: Reformulated with excipient modification to optimize pharmacokinetic profile and target new symptoms like fatigue in narcolepsy patients.

HBS-102 (MCHR1 antagonist)

• Description: Undergoing development for sleep/wake disorders.

BP1.15205 (orexin-2 receptor agonist)

• Description: Another product in development.

ZYN002 (cannabidiol gel)

• Description: Targeting neurobehavioral conditions such as Fragile X Syndrome (FXS) and 22q11.2 Deletion Syndrome (22q).

EPX-100 (clemizole hydrochloride)

• Description: Targeting rare epilepsy conditions such as Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS).

EPX-200 (lorcaserin)

• Description: Focused on Developmental and Epileptic Encephalopathy (DEE).

Recent Developments

• New Developments in Company:

• Acquired Zynerba Pharmaceuticals in 2023.

• Acquired Epygenix Therapeutics in 2024.

• Signed agreements with Bioprojet to expand opportunities in narcolepsy in 2022.

• New Partnerships: No specific information mentioned regarding recent partnerships.

• Financial Reporting: Scheduled to report third-quarter financial results on October 29, 2024.

• Organizational Highlights:

• Added to the S&P SmallCap 600® Index and the NASDAQ Biotechnology Index in 2021.

• Joined the NASDAQ via IPO launch in 2020.

• Received FDA approval for its first commercial product in 2019.

Conclusion

This market research report focuses on Harmony Biosciences' strong commitment to addressing unmet medical needs for rare neurological diseases. The company demonstrates robust development and expansion through notable product approvals, strategic partnerships, and acquisitions. Despite some areas lacking detailed public information, Harmony Biosciences continues to expand its impact through patient-focused innovative drug development.